Compare Incyte Corporation (INCY) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Direxion Daily S&P 500 Bull 3X Shares trades at $298.51 (market cap $7.36B). The key difference: Incyte Corporation is far larger — about 3.1× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| INCY | SPXL | |
|---|---|---|
Market Cap | $22.85B | $7.36B |
Volume | 1,927,029 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $301.38 |
52-Week Low | $83.80 | $170.20 |
Typical Hold Time | 33 Days | 32 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
SPXL trades at $298.10, up 0.42% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 66.91 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation concerns despite strong earnings growth projections of 35% for 2026. The index faces concentration risks with top holdings accounting for 40% of value.
Outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though profit growth is expected to slow to 15% in 2027. Key risks include market concentration, geopolitical uncertainty, and potential Fed policy impacts. Technical support at $289 and resistance at $300 will be critical near-term levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
